Table 2.
Risk of hepatitis B virus (HBV) reactivation for different AIHA treatments according to viral status.
| Drug | Viral Status | Risk Category |
|---|---|---|
| High-dose steroids * | HBsAg+HBsAg-/antiHBc+ | high moderate |
| Moderate-dose steroids ** | HBsAg+HBsAg-/antiHBc+ | moderate low |
| Short-term low-dose steroids *** | irrelevant | low |
| Rituximab | irrelevant | high |
| Cyclosporine | irrelevant | moderate |
| Methotrexate | irrelevant | low |
| Azathioprine | irrelevant | low |
| Bortezomib | irrelevant | moderate |
HBsAg: hepatitis B surface antigen, antiHBc: hepatitis B core antibodies, high risk: >10% rate of HBV reactivation, moderate risk: 1–10% rate of HBV reactivation, low risk: <1% rate of HBV reactivation, * >20 mg prednisone-equivalent dose/day, ** 10–20 mg prednisone-equivalent dose/day, *** <10 mg prednisone-equivalent dose/day over 4 weeks.